Skip to content

Efficacy and Feasibility of an Intermittent Weight Loss Program.

Efficacy and Feasibility of an Intermittent Weight Loss Program: A Pilot Study.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00395356
Enrollment
20
Registered
2006-11-02
Start date
2005-09-30
Completion date
2007-06-30
Last updated
2006-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Diet, Caloric restriction, Intermittent diet, Obesity, Postmenopausal women

Brief summary

The goal of the study is to measure the effect of an approach including phases of active weight loss broken by weight stabilisation periods (named intermittent weight loss) on the metabolic profile. First, the intermittent weight loss approach will contribute to create an artificial transitory steady state during the weight loss treatment that will help to minimize the adverse effects of the standard approach on muscle mass and resting metabolic rate. Second, despite a comparable fat mass loss, the intermittent weight loss approach will improve the metabolic profile to a greater degree compared to the standard approach. Finally, the intermittent weight loss approach will be associated with less weight regain after the treatment since the beneficial effect on muscle mass and metabolic rate.

Detailed description

Excessive levels of body fat are associated with metabolic disturbances predictive of an increased risk of coronary heart disease (CAD). It is presently unclear as to the magnitude of weight loss needed to accrue metabolic benefits. Despite the effectiveness of weight loss to reduce obesity levels, studies have shown that only minor decreases in body weight (5-10%) are needed to clinically improve CAD risk factors. Our data suggested that a 10% reduction in body weight is as effective in improving the metabolic profile as a 20% decrease in body weight. Thus, the question are : Is it possible to further improve the metabolic profile over that 5-10% weight loss threshold? and Could several 5-10% body weight loss (intermittent weight loss approach) have additive effects on the metabolic profile?. We would like to follow-up on these observation to better understand 1) the association between weight loss and improvements in the metabolic profile and 2) why minor decreases in body composition and body fat distribution are as effective as more important reduction.

Interventions

Sponsors

Fonds de la Recherche en Santé du Québec
CollaboratorOTHER_GOV
Université de Sherbrooke
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
51 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Women who had stopped menstruating for more than 1 year * Waist circumference \> 90 cm * Sedentary (\< 2 times a week of structured exercise) * Non-smokers * Low to moderate alcohol consumers (\< 2 drinks per day).

Exclusion criteria

* We excluded subjects with the following conditions based on medical history and physical examination and on laboratory testing of kidney and liver functions, serum TSH, fasting glucose and lipid profile, and 75g-OGTT * Cardiovascular disease, peripheral vascular disease or stroke * Diabetes * Moderate to severe hypertension (resting blood pressure \> 170/100 mm Hg); * Body weight fluctuation \> 5 kg in the previous 6 months * Thyroid or pituitary disease * Hormonal replacement therapy at any time during the previous 6 months * Medication that could affect the metabolic profile

Design outcomes

Primary

MeasureTime frame
Body composition (fat mass and lean body mass): after 0, 5, 10, 15, 20 and 25 weeks, as well as 12-month post-intervention

Secondary

MeasureTime frame
Resting blood pressure: baseline, 5, 10, 15, 20 and 25 weeks, as well as 12-month post-intervention
OGTT: baseline and 25 weeks
Dietary habits: baseline,25 weeks and 12-month post-intervention
Fasting lipids: baseline, 5, 10, 15, 20 and 25 weeks, as well as 12-month post-intervention
Resting metabolic rate: baseline, 5, 10, 15, 20 and 25 weeks, as well as 12-month post-intervention

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026